{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-25-000074","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.435908+00:00","generated_at":"2026-05-23T03:23:34.437586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NeoGenomics Q1 revenue up 8% to $168M; adjusted EBITDA turns positive at $7M","bullets":["Consolidated revenue $168M (+8% YoY); net loss improved 4% to $26M.","Adjusted EBITDA $7M vs $3M prior year, up 102%.","Revenue per clinical test $459 (+3%).","Revised FY2025 guidance: revenue $747-759M, adj. EBITDA $55-58M.","Pathline acquisition adds $12-14M expected revenue to 2025 guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-25-000074","json":"https://secwatch.observer/filing/0001077183-25-000074.json","markdown":"https://secwatch.observer/filing/0001077183-25-000074.md","text":"https://secwatch.observer/filing/0001077183-25-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000074/0001077183-25-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000074/neo-20250429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T03:23:34.437586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}